Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
valuation ratios | |
|---|---|
| pe ratio | -4.17 |
| peg ratio | -0.04 |
| price to book ratio | 2.21 |
| price to sales ratio | 18.90 |
| enterprise value multiple | -4.55 |
| price fair value | 2.21 |
profitability ratios | |
|---|---|
| gross profit margin | -13.57% |
| operating profit margin | -473.22% |
| pretax profit margin | -458.02% |
| net profit margin | -451.26% |
| return on assets | -41.37% |
| return on equity | -58.43% |
| return on capital employed | -49.25% |
liquidity ratio | |
|---|---|
| current ratio | 4.22 |
| quick ratio | 3.90 |
| cash ratio | 1.39 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 136.47 |
| operating cycle | 360.50 |
| days of payables outstanding | 112.09 |
| cash conversion cycle | 248.42 |
| receivables turnover | 1.63 |
| payables turnover | 3.26 |
| inventory turnover | 2.67 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.08 |
| debt equity ratio | 0.10 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.09 |
| interest coverage | -123.34 |
| cash flow to debt ratio | -4.61 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.23 |
| cash per share | 1.31 |
| operating cash flow per share | -1.20 |
| free cash flow operating cash flow ratio | 1.03 |
| cash flow coverage ratios | -4.61 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -34.87 |
Frequently Asked Questions
Iovance Biotherapeutics, Inc. (IOVA) published its most recent earnings results on 07-11-2024.
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)'s trailing twelve months ROE is -58.43%.
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Iovance Biotherapeutics, Inc. (IOVA) currently has a ROA of -41.37%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
IOVA reported a profit margin of -451.26% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
Apple's current ratio, which measures its ability to pay short-term obligations, was 4.22 in the most recent quarter. The quick ratio stood at 3.90, with a Debt/Eq ratio of 0.10.